NuCana (NCNA) Change in Account Payables (2017 - 2025)
NuCana (NCNA) reported Change in Account Payables of -$1.5 million for Q4 2025, up 64.64% on a YoY basis from -$920241.2 in Q4 2024, and down 299.43% sequentially from $759690.9 in Q3 2025.
NuCana (NCNA) Change in Account Payables (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Change in Account Payables data on file, last reported at -$1.5 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Account Payables rose 64.64% year-over-year to -$1.5 million; the trailing twelve-month figure through Dec 2025 stood at -$5.1 million (down 466.9% YoY), and the FY2025 full-year result was -$2.9 million, down 236.08% from the prior year.
- Change in Account Payables slipped to -$1.5 million in Q4 2025, from $759690.9 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $3.0 million in Q1 2024 to a low of -$4.3 million in Q4 2024.
- A 5-year average of -$221843.8 and a median of $174225.1 in 2024 frame the typical range for Change in Account Payables.
- Peak annual rise in Change in Account Payables reached 3041.58% in 2021, while the deepest fall reached 293.34% in 2021.
- Tracing NCNA's Change in Account Payables over 5 years: stood at -$2.8 million in 2021, then surged by 74.72% to -$702697.3 in 2022, then plunged by 217.75% to -$2.2 million in 2023, then plunged by 91.88% to -$4.3 million in 2024, then soared by 64.64% to -$1.5 million in 2025.
- Business Quant data shows NCNA's Change in Account Payables at -$1.5 million in Q4 2025, $759690.9 in Q3 2025, and -$4.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.52 Mn |
| Dec 31, 2025 | -1.52 Mn |
| Sep 30, 2025 | 759,690.89 |
| Sep 30, 2025 | 759,690.89 |
| Dec 31, 2024 | -4.28 Mn |
| Dec 31, 2024 | -4.28 Mn |
| Sep 30, 2024 | -85,753.81 |
| Sep 30, 2024 | -85,753.81 |
| Jun 30, 2024 | 434,203.94 |
| Jun 30, 2024 | 434,203.94 |
| Mar 31, 2024 | 3.03 Mn |
| Mar 31, 2024 | 3.03 Mn |
| Dec 31, 2023 | -2.23 Mn |
| Dec 31, 2023 | -2.23 Mn |
| Sep 30, 2023 | 627,008.97 |
| Sep 30, 2023 | 627,008.97 |
| Jun 30, 2023 | -1.27 Mn |
| Jun 30, 2023 | -1.27 Mn |
| Mar 31, 2023 | 1.08 Mn |
| Mar 31, 2023 | 1.08 Mn |